4433-40-3

基本信息
5-羥甲基尿嘧啶
2,4-二羥基-5-羥甲基嘧啶
5-(羥甲基)尿嘧啶
5-羥甲基尿間二氮苯
5-(HYDROXYMETHYL)-2,4(1H,3H)PYRIMIDINEDIONE
5-HYDROXYMETHYLURACIL
5-(HYDROXYMETHYL)URACIL HYDRATE
5-HYDROXYMETHYLURACYL
AURORA KA-547
HYDROXYMETHYL URACIL
RARECHEM AH CK 0115
TIMTEC-BB SBB000084
3h)-pyrimidinedione,5-(hydroxymethyl)-4(1h
5-(hydroxymethyl)-uraci
2,4(1H,3H)-Pyrimidinedione, 5-(hydroxymethyl)- (9CI)
5-(Hydroxymethyl)uracil,98%
5-(hydroxymethyl)pyrimidine-2,4-dione
uracil-5-methanol
5-(Hydroxymethyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
制備方法

50-00-0

66-22-8

4433-40-3
實施例1a 5-(羥甲基)-1,3-二氫嘧啶-2,4-二酮的合成:在配備有機械攪拌器、溫度計、冷凝管及氮氣鼓泡入口的2L三頸燒瓶中,依次加入尿嘧啶(185.0g,1.65mol)、多聚甲醛(61.50g,2.05mol,作為甲醛源)及氫氧化鉀(59.95g,928.5mmol,純度86.9%)的水溶液(1.445L)。將反應(yīng)混合物于50-52℃下攪拌68小時,通過TLC監(jiān)測反應(yīng)完成。反應(yīng)完成后,將混合物在60℃/14mmHg下減壓濃縮至約1mL。向濃縮物中加入500mL水,隨后用丙酮(500mL)稀釋。過濾收集生成的白色沉淀,用丙酮洗滌,抽濾干燥,再于50℃/25mmHg下干燥,得到粗品5-(羥甲基)-1,3-二氫嘧啶-2,4-二酮(250g)。將合并的母液和洗滌液濃縮至約1mL,加入100mL水及鹽酸羥胺(27.52g,396.0mmol)的水溶液(100mL)。過濾收集第二批白色沉淀,用丙酮洗滌,抽濾干燥,得到第二批粗品5-(羥甲基)-1,3-二氫嘧啶-2,4-二酮(34g)。合并兩批粗品(總計244g,收率104%),直接用于后續(xù)步驟。
參考文獻(xiàn):
[1] Patent: US2004/38995, 2004, A1. Location in patent: Page/Page column 4-6
[2] Synlett, 2002, # 12, p. 2043 - 2044
[3] Patent: US2016/75720, 2016, A1. Location in patent: Paragraph 0321
[4] Canadian Journal of Chemistry, 2007, vol. 85, # 4, p. 302 - 312
[5] Canadian Journal of Chemistry, 2005, vol. 83, # 10, p. 1731 - 1740
常見問題列表
Human Endogenous Metabolite
|